How I treat the antiphospholipid syndrome.
This article discusses how we approach medical decision making in the treatment of the various facets of the antiphospholipid syndrome (APS), including secondary prophylaxis in the setting of venous and arterial thrombosis, as well as treatment for the prevention of recurrent miscarriages and fetal death. The role of primary thromboprophylaxis is also discussed in depth. Great emphasis is given to incorporating the most up-to-date and relevant evidence base both from the APS literature, and from large, recent, randomized controlled trials (RCTs) of primary and secondary thrombotic prophylaxis in the general population setting (ie, the population that has not been specifically investigated for APS).
Giannakopoulos
Bill
B
Department of Immunology, Allergy and Infectious Diseases, St George Hospital, Kogarah, Australia. billgianna@hotmail.com
Krilis
Steven A
SA
D000026:Abortion, Habitual / Q000517:prevention & control; D016736:Antiphospholipid Syndrome / Q000628:therapy*; D005260:Female; D005313:Fetal Death / Q000517:prevention & control; D006801:Humans; D008297:Male; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D013927:Thrombosis / Q000517:prevention & control